Document is current
Any future updates will be listed below
-
Authors
Elamaa, Harri
Kaakinen, Mika
Nätynki, Marjut
Szabo, Zoltan
Ronkainen, Veli-Pekka
Äijälä, Ville
Mäki, Joni M.
Kerkelä, Risto
Myllyharju, Johanna
Eklund, Lauri https://orcid.org/0000-0002-3177-7504
-
Funding
Funding for this research was provided by:
Terveyden Tutkimuksen Toimikunta (251314, 136880, 251314)
University of Oulu including Oulu University Hospital
- License Information
-
More Information
Article History
Received: 17 February 2021
Accepted: 29 November 2021
First Online: 8 January 2022
Disclosures
:
: JM owns equity in FibroGen Inc., which develops HIF-P4H inhibitors as potential therapeutics. This company supports research in the JM group. All other authors declare no competing financial interests.
